Sponsored By

Boston Scientific and OrbusNeich Resolve Stent Patent Tussle

Qmed Staff

September 17, 2013

1 Min Read
Boston Scientific and OrbusNeich Resolve Stent Patent Tussle

OrbusNeich and Boston Scientific agreed to a ceasefire over a stent-related legal spat. Under the agreement, Boston Scientific will make a one-time payment to OrbusNeich to settle outstanding lawsuits.

While the settlement sum wasn't disclosed, OrbusNeich has agreed to end its lawsuit against the Massachusetts-based medical device manufacturer. While the settlement will cover all stent-related lawsuits, it will not cover future financial obligations.

In the patent spat, OrbusNeich claimed that Boston Scientific's stents violated several of its patents. In particular, Boston Scientific's Promus Premier and Promus Element are alleged to have infringed on OrbusNeich's intellectual property.

OrbusNeich first filed a lawsuit against Boston Scientific in Germany. Over time, its litigation expanded to the United States, the United Kingdom, the Netherlands and Ireland.

In April of this year, OrbusNeich managed to win a German injunction against Boston Scientific. In that injunction, Boston Scientific was banned from selling its patent-infringing stents. In May, OrbusNeich called the German police on Boston Scientific, requesting that they seize infringing stents from Boston's German headquarters.

For now, the legal tussle between these two giants appears to be over. While neither company shared further comments with the press earlier today, a joint statement by both companies indicates that business will be back to usual.

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like